Drug Profile


Alternative Names: COX 189; Joicela; Prexige

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis
  • Class Antirheumatics; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Phenylacetates; Small molecules
  • Mechanism of Action Cyclo-oxygenase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Marketed Acute pain; Dysmenorrhoea; Gout; Osteoarthritis
  • No development reported Dental pain; Postoperative pain; Rheumatoid arthritis

Most Recent Events

  • 31 Dec 2011 Discontinued - Phase-III for Osteoarthritis in Israel (PO)
  • 31 Dec 2011 Discontinued - Phase-III for Osteoarthritis in South Africa (PO)
  • 31 Dec 2011 Discontinued - Preregistration for Osteoarthritis in European Union (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top